Literature DB >> 32135114

Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy.

Laura Pala1, Fabio Conforti2, Aron Goldhirsch3.   

Abstract

Entities:  

Year:  2020        PMID： 32135114     DOI： 10.1016/S1470-2045(20)30072-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Authors:  Masato Takahashi; Eriko Tokunaga; Joji Mori; Yoshinori Tanizawa; Jan-Stefan van der Walt; Tsutomu Kawaguchi; Matthew P Goetz; Masakazu Toi
Journal:  Breast Cancer       Date:  2021-10-18       Impact factor: 4.239

2.  Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.

Authors:  Norikazu Masuda; Yucherng Chen; Tsutomu Kawaguchi; Koji Dozono; Masakazu Toi
Journal:  Cancer Manag Res       Date:  2022-03-19       Impact factor: 3.989

3.  Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

Authors:  Jeremy Mason; Yutao Gong; Laleh Amiri-Kordestani; Suparna Wedam; Jennifer J Gao; Tatiana M Prowell; Harpreet Singh; Anup Amatya; Shenghui Tang; Richard Pazdur; Peter Kuhn; Gideon M Blumenthal; Julia A Beaver
Journal:  JCO Clin Cancer Inform       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.